PDCD1 and paraneoplastic neurologic syndrome: Therefore, in this study we specifically focused on PD-1/PD-L1 inhibitor–related PNS, systematically evaluating their clinical characteristics and antibody profiles and analyzing their impact on prognosis, with the aim of providing a basis for early risk stratification and individualized intervention strategies.